SCHEMBL2985359

SCHEMBL2985359

O=C(c1ccccc1)C(O)CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 0.54
CES2 O00748 3/20 0.54
LMNA P02545 1/20 0.54
TDP1 Q9NUW8 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MDM2 Q00987 1/20 0.50
ALKBH5 Q6P6C2 1/20 0.50
PGR P06401 1/20 0.46
ADRA2A P08913 1/20 0.46
ADRA2B P18089 1/20 0.46
HTR2A P28223 1/20 0.46
HRH1 P35367 1/20 0.46
KCNH2 Q12809 1/20 0.46
MAPK1 P28482 3/20 0.44
MAPT P10636 3/20 0.44
CYP3A4 P08684 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Terephthalic Acid SCHEMBL27941219 0.92 TSHR (0.54) CES1CES2LMNATDP1L3MBTL1
SCHEMBL11094690 0.83 CES1 (0.50) CES1CES2LMNATDP1L3MBTL1
SCHEMBL3319973 0.80 CES1 (0.52) CES1CES2LMNATDP1L3MBTL1
SCHEMBL10799605 0.80 ALKBH5 (0.53) CES1CES2LMNATDP1L3MBTL1
SCHEMBL3323928 0.80 CES1 (0.52) CES1CES2LMNATDP1L3MBTL1
SCHEMBL289556 0.80 PGR (0.53) CES1CES2LMNATDP1L3MBTL1
SCHEMBL8780874 0.80 CES1 (0.52) CES1CES2LMNATDP1L3MBTL1
SCHEMBL3319972 0.80 CES1 (0.52) CES1CES2LMNATDP1L3MBTL1
SCHEMBL1822406 0.80 PGR (0.53) CES1CES2LMNATDP1L3MBTL1
SCHEMBL6425248 0.80 CES1 (0.52) CES1CES2LMNATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104478919-B A kind of method of synthesis of chiral silane compound 浙江大学 2018-02-02 CN claimed
CN-104478919-A Method for synthesizing chiral silane compound UNIV ZHEJIANG 2015-04-01 CN claimed
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles BIODERM RESEARCH (US) 2008-10-16 US claimed
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction BIODERM RESEARCH (US) 2008-10-16 US claimed
US-7427690-B2 Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration BIODERM RESEARCH (US) 2008-09-23 US claimed
US-20070099886-A1 Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration BIODERM RESEARCH (US) 2007-05-03 US claimed
US-20060074108-A1 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition BIODERM RESEARCH (US) 2006-04-06 US claimed
US-20050271608-A1 Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives GUPTA SHYAM K 2005-12-08 US claimed
CN-104478919-B A kind of method of synthesis of chiral silane compound 浙江大学 2018-02-02 CN disclosed
CN-104478919-A Method for synthesizing chiral silane compound UNIV ZHEJIANG 2015-04-01 CN disclosed
US-8227426-B2 Chiral complexes of ascorbic acid with natural antioxidant and anti-inflammatory ketones including aloe, citrus, ginger, and mango for skin and hair care ISLAND KINETICS INC. (US) 2012-07-24 US disclosed
US-20110059907-A1 Chiral Complexes of Ascorbic Acid with Natural Antioxidant and Anti-Inflammatory Ketones Including Aloe, Citrus, Ginger, and Mango for Skin and Hair Care ISLAND KINETICS INC. (US) 2011-03-10 US disclosed
US-7834210-B2 Hair loss prevention by natural amino acid and peptide complexes BIODERM RESEARCH (US) 2010-11-16 US disclosed
US-7777073-B2 Topical delivery system for antiaging and skin whitening agents BIODERM RESEARCH (US) 2010-08-17 US disclosed
US-20080287536-A1 Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes BIODERM RESEARCH (US) 2008-11-20 US disclosed
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles BIODERM RESEARCH (US) 2008-10-16 US disclosed
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction BIODERM RESEARCH (US) 2008-10-16 US disclosed
US-7427690-B2 Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration BIODERM RESEARCH (US) 2008-09-23 US disclosed
US-20080139507-A1 Method of Treating Skin Condition Including Acne, Skin Aging, Body Odor & Diaper Rash by Zinc Zeolite Clathrates BIODERM RESEARCH (US) 2008-06-12 US disclosed
US-20070099886-A1 Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration BIODERM RESEARCH (US) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059907-A1 Chiral Complexes of Ascorbic Acid with Natural Antioxidant and Anti-Inflammatory Ketones Including Aloe, Citrus, Ginger, and Mango for Skin and Hair Care GLA, LPO, PLOD3 CES1 482/4885CES2 1767/4885LMNA 1106/4885
US-20080287536-A1 Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes MMP17, MC1R, TYR CES1 2284/4885CES2 2279/4885LMNA 691/4885
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction PSMB1, PLOD3, CUTA CES1 1542/4885CES2 1968/4885LMNA 847/4885
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles PROC, COL1A1, CUTA CES1 452/4885CES2 1727/4885LMNA 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.